Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Akero Therapeutics, Inc. (AKRO)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 61,281,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Akero Therapeutics is a clinical-stage company developing treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. Co.'s primary product candidate, efruxifermin, is an analog of fibroblast growth factor 21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 200,000 800,000 1,200,000
Total Buy Value $0 $3,677,505 $22,531,214 $32,931,214
Total People Bought 0 1 1 1
Total Buy Transactions 0 3 8 9
Total Shares Sold 110,332 176,617 519,059 3,046,073
Total Sell Value $3,553,208 $4,744,191 $22,222,916 $129,158,693
Total People Sold 5 5 7 9
Total Sell Transactions 9 19 44 86
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 303
  Page 5 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Rolph Timothy Chief Scientific Officer   •       –      –    2022-12-28 4 AS $50.00 $85,006 D/D (1,700) 203,032     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2022-12-28 4 OE $28.35 $48,195 D/D 1,700 204,732     -
   White William Richard Chief Financial Officer   •       –      –    2022-12-28 4 AS $49.76 $49,714 D/D (999) 23,624     -
   White William Richard Chief Financial Officer   •       –      –    2022-12-28 4 OE $7.01 $7,002 D/D 999 24,623     -
   White William Richard Chief Financial Officer   •       –      –    2022-12-27 4 AS $49.77 $945,609 D/D (19,001) 23,624     -
   White William Richard Chief Financial Officer   •       –      –    2022-12-27 4 OE $7.01 $133,178 D/D 19,001 42,625     -
   Young Jonathan Chief Operating Officer   •       –      –    2022-12-27 4 AS $49.57 $619,609 D/D (12,500) 182,449     -
   Young Jonathan Chief Operating Officer   •       –      –    2022-12-27 4 OE $0.62 $75,352 D/D 12,500 194,949     -
   Cheng Andrew President & CEO   •       •      –    2022-12-16 4 OE $0.62 $5,228 D/D 8,500 370,999     -
   Yale Catriona Chief Development Officer   •       –      –    2022-12-12 4 AS $43.18 $216,137 D/D (5,000) 86,268     -
   Young Jonathan Chief Operating Officer   •       –      –    2022-12-09 4 A $0.00 $0 D/D 19,195 182,449     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2022-12-09 4 A $0.00 $0 D/D 19,195 203,032     -
   Cheng Andrew President & CEO   •       •      –    2022-12-09 4 A $0.00 $0 D/D 52,351 362,499     -
   White William Richard Chief Financial Officer   •       –      –    2022-12-09 4 A $0.00 $0 D/D 19,195 23,624     -
   Yale Catriona Chief Development Officer   •       –      –    2022-12-09 4 A $0.00 $0 D/D 19,195 91,268     -
   Montrago Trustees Ltd Former 10% owner   –       –      –    2022-12-01 4 S $43.50 $71,166,000 I/I (1,636,000) 3,271,829     -
   Cheng Andrew President & CEO   •       •      –    2022-12-01 4 AS $46.07 $460,700 D/D (10,000) 310,148     -
   Cheng Andrew President & CEO   •       •      –    2022-12-01 4 OE $0.62 $6,150 D/D 10,000 320,148     -
   Harrison Seth Loring Director   –       •      –    2022-11-30 4 S $46.44 $564,673 I/I (12,030) 148,063     -
   Harrison Seth Loring Director   –       •      –    2022-11-30 4 S $46.44 $521,067 D/D (11,101) 136,301     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2022-11-16 4 AS $45.45 $179,464 D/D (3,947) 183,837     -
   Rolph Timothy Chief Scientific Officer   •       –      –    2022-11-15 4 AS $45.04 $141,343 D/D (3,138) 187,784     -
   Yale Catriona Chief Development Officer   •       –      –    2022-11-10 4 AS $39.41 $197,105 D/D (5,000) 72,073     -
   Cheng Andrew President & CEO   •       •      –    2022-11-01 4 AS $42.15 $434,183 D/D (10,000) 310,148     -
   Cheng Andrew President & CEO   •       •      –    2022-11-01 4 OE $0.62 $6,150 D/D 10,000 320,148     -
  303 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 5 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us